fluoxetine has been researched along with Diffuse Parenchymal Lung Disease in 6 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "36 cases of interstitial lung disease related to fluoxetine were retrieved from the VigiAccess database (updated to July 2016), and 36 reports were found in EudraVigilance database (updated to June 2016)." | 2.55 | Interstitial lung disease induced by fluoxetine: Systematic review of literature and analysis of Vigiaccess, Eudravigilance and a national pharmacovigilance database. ( Bocchetta, A; Deidda, A; Del Zompo, M; Micheletto, L; Pisanu, C; Stochino, ME, 2017) |
| "Fluoxetine treatment effects were determined by evaluating respiratory mechanics (elastance/resistance) and exhaled nitric oxide, as well as mononuclear and polymorphonuclear cell recruitment into the lungs, in an experimental guinea pig model." | 1.34 | Morphological and functional determinants of fluoxetine (Prozac)-induced pulmonary disease in an experimental model. ( Capelozzi, MA; Capelozzi, VL; Leick-Maldonado, EA; Martins, MA; Parra, ER; Tibério, IF, 2007) |
| "Fluoxetine (Prozac) is a new anti-depressant introduced on the marked in France since 1989." | 1.30 | [Interstitial lung disease linked to fluoxetine]. ( Lamblin, C; Vandezande, LM; Wallaert, B, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Wen, C | 1 |
| He, T | 1 |
| Liu, B | 1 |
| Deidda, A | 1 |
| Pisanu, C | 1 |
| Micheletto, L | 1 |
| Bocchetta, A | 1 |
| Del Zompo, M | 1 |
| Stochino, ME | 1 |
| Capelozzi, MA | 1 |
| Leick-Maldonado, EA | 1 |
| Parra, ER | 1 |
| Martins, MA | 1 |
| Tibério, IF | 1 |
| Capelozzi, VL | 1 |
| Miller, LG | 1 |
| Vandezande, LM | 1 |
| Lamblin, C | 1 |
| Wallaert, B | 1 |
| Braun, D | 1 |
| Nippert, B | 1 |
| Loeuille, D | 1 |
| Blain, H | 1 |
| Tréchot, P | 1 |
1 review available for fluoxetine and Diffuse Parenchymal Lung Disease
| Article | Year |
|---|---|
Interstitial lung disease induced by fluoxetine: Systematic review of literature and analysis of Vigiaccess, Eudravigilance and a national pharmacovigilance database.
Topics: Animals; Antidepressive Agents; Databases, Factual; Fluoxetine; Humans; Lung; Lung Diseases, Interst | 2017 |
5 other studies available for fluoxetine and Diffuse Parenchymal Lung Disease
| Article | Year |
|---|---|
Identifying interstitial lung disease associated chemicals by integrating transcriptome-wide association study and chemical-gene interaction networks.
Topics: Cholecalciferol; Fluoxetine; Humans; Lung Diseases, Interstitial; Quality of Life; Transcriptome | 2023 |
Morphological and functional determinants of fluoxetine (Prozac)-induced pulmonary disease in an experimental model.
Topics: Airway Resistance; Animals; Antidepressive Agents, Second-Generation; Bronchoconstriction; Disease M | 2007 |
I have read about a patient in whom fluoxetine use may have caused lung damage. Can you comment on the likelihood that there was a cause and effect relationship in this published case?
Topics: Dose-Response Relationship, Drug; Fluoxetine; Humans; Lung Diseases, Interstitial; Risk Factors | 1993 |
[Interstitial lung disease linked to fluoxetine].
Topics: Aged; Antidepressive Agents, Second-Generation; Bronchoalveolar Lavage Fluid; Fluoxetine; Humans; Lu | 1997 |
[Interstitial pneumopathy induced by fluoxetine].
Topics: Adult; Antidepressive Agents, Second-Generation; Dyspnea; Female; Fluoxetine; Humans; Lung Diseases, | 1999 |